TGTX TG THERAPEUTICS INC
2026Q1 · CUSIP 88322Q108 · Sector: Healthcare & Biotech
Neutral · No signal
Holders
358
Δ holders QoQ
+7
Breadth percentile
Top 37%
Whale holders
164
Δ whales
+6
Inst. holding value
$3.5B
New positions
67
Closed positions
60
Price momentum (1Q)
+35.9%
Put / Call
10/12
Breadth history (34 quarters)
Past Lit Events & Aftermath 10 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2025Q1 | Top 4% | -20.2% | -12.3% |
| 2024Q3 | Top 5% | +4.3% | +15.6% |
| 2024Q2 | Top 15% | +39.7% | +40.4% |
| 2023Q2 | Top 6% | +1.9% | +34.0% |
| 2023Q1 | Top 11% | -67.2% | -64.4% |
| 2022Q3 | Top 13% | +113.2% | +254.0% |
| 2020Q4 | Top 7% | -27.7% | -52.4% |
| 2020Q2 | Top 13% | +29.4% | +101.5% |
| 2020Q1 | Top 8% | +14.5% | +48.2% |
| 2018Q1 | Top 12% | -19.2% | -63.2% |
Options Sentiment
Put holders
10
QoQ: +1
Call holders
12
QoQ: +1
See methodology →
Fundamentals
PE (TTM)
19.3
EPS (TTM)
$2.86
EPS YoY
+1044.0%
Revenue (TTM)
$0.7B
Revenue YoY
+81.3%
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
P/E (TTM) over time
P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden
As of 2026-03-31 · SEC filings (XBRL)